January 10, 2020
Authored and Edited by Oulu (Lulu) Wang, Ph.D.; Brooke M. Wilner; Sydney R. Kestle; Elizabeth D. Ferrill
The petitioner in Athena Diagnostics, Inc. v. Mayo Collaborative Services, No. 19-430, has asked the Supreme Court to consider the question whether diagnostic claims are patent eligible.
In 2015, Athena Diagnostics, Inc. (“Athena”) sued Mayo Collaborative Services (“Mayo”) for infringing its patent covering a method for diagnosing myasthenia gravis by detecting autoantibodies to muscle specific tyrosine kinase (MuSK). The inventors had discovered both MuSK autoantibodies (naturally occurring, but previously unknown) and the link between MuSK autoantibodies and myasthenia gravis (naturally occurring, but previously unknown). In 2017, the district court held these claims were patent ineligible.
The Federal Circuit affirmed, citing Mayo, holding that these diagnostic claims were directed to a natural law—namely, the correlation between the presence of naturally occurring MuSK autoantibodies in bodily fluid and MuSK-related neurological diseases—and recited conventional techniques to detect that natural law. Athena petitioned for rehearing en banc, which the Federal Circuit denied. The Federal Circuit issued eight opinions concurring with and dissenting from that denial.
Athena petitioned the Supreme Court for review. In its petition, Athena argued the eight opinions concurring and dissenting from the denial of rehearing en banc evidence “an unprecedented cry for help from [the Supreme Court] to clarify the patent eligibility of medical diagnostic tests.” Athena highlighted issues with Section 101 that it contends require clarification. According to Athena:
Athena noted that, since the Supreme Court’s decision in Mayo, “the Federal Circuit has invalidated every diagnostic claim to come before it as ineligible subject matter.” And, it noted the USPTO’s rejection rate for diagnostic applications rose from 7% before Mayo to a high of 64% after Mayo.
On November 22, 2019, Mayo filed a brief in opposition, contending Athena’s patent is directed to a natural law, and the Supreme Court has already held in Mayo that claims to a natural law using only routine and conventional detection techniques are not patent eligible. Mayo disputes any negative impact to the diagnostics field and asserts a change to Section 101 eligibility is a matter reserved for Congress.
On December 9, 2019, Athena filed its reply brief, emphasizing that certiorari should be granted to clarify confusion surrounding Section 101. Athena emphasized the amicus briefs filed; the split in the Federal Circuit; and the United States’ suggestion in its brief in Hikma Pharms. USA Inc. v. Vanda Pharms. Inc. that the Court should grant certiorari in this case.
The Supreme Court has not yet decided the disposition of Athena’s petition.
Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.